By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing ...

Sarepta stock jumped Monday after the company unveiled three-year test results for its embattled gene therapy, Elevidys.

A University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...

GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.

Doctors have delivered gene therapy during heart bypass surgery for the first time, aiming to strengthen blood vessels ...

Researchers complete final analysis of a phase 3 study of men with hemophilia B receiving intravenous etranacogene dezaparvovec.

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for a muscle‑wasting disorder slowed disease progression and showed ...